CLOs on the Move

Spectral MD

www.spectralmd.com

 
Spectral MD is a predictive analytics company that develops proprietary optical technology and AI algorithms to help clinicians accurately make better and faster treatment decisions for burns, chronic wounds, and other pathological conditions of the skin. Spectral MD is located in the heart of Uptown Dallas, TX and London, UK.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Vincent Capone
General Counsel Profile

Similar Companies

Prowest Dental Lab

Prowest Dental Lab Ltd is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Zipline Medical

ZipLine® Medical is developing and commercializing innovative tissue repair devices to address the clinical need for rapid, non-invasive and easy-to-use skin closure. ZipLine`s PRELOC™ technology platform provides uniform closure forces while minimizing scar-promoting tension along the wound. Utilizing our patented technology, we believe that physicians can achieve the best of both worlds — the speed of staples with the cosmetic outcome of a meticulous suture closure. Our initial strategy focuses on procedures where the non-invasive, speed and cosmetic benefits of our technology have the greatest impact. Since skin closure is a part of most surgical procedures, our technology platform has broad application across various surgical specialties and emergency medicine. ZipLine Medical was founded in 2009 by Amir Belson, M.D. and is located in Silicon Valley, with access to a wealth of expertise in medical device research and development

Mental Health Corporation of Denver

Mental Health Corporation of Denver is a Denver, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sequana Medical

Sequana Medical is a Saratoga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.